eBioscience Contribution Pushes Affymetrix Q2 Revenues up 20 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Affymetrix said after the close of the market on Wednesday that its second-quarter revenues climbed 20 percent year over year as product sales increased 27 percent on the addition of the eBioscience business.

Investors reacted positively to the results, sending Affy's shares up nearly 11 percent to $4.20 in Thursday morning trade on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.